Sotera Health Company SHC
18.34
(0.11)
(0.60%)
as of 25 Sep
- Market cap
- $5.3B
- P/E
- 32.1×
Follow SHC
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
82.79 | 65.33 | 34.98 | 31.14 |
P/S ratio |
3.88 | 4.30 | 3.44 | 4.17 | |
P/FCF ratio |
51.59 | 33.58 | 42.18 | 45.01 | |
P/Operating CF |
62.80 | 48.58 | 138.79 | 57.32 | |
P/B ratio |
8.12 | 8.27 | 6.56 | 7.62 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.57 | 5.93 | 5.05 | 5.71 | |
EV/EBITDA |
12.98 | 13.68 | 11.69 | 13.10 | |
EV/Operating CF |
26.71 | 24.02 | 22.98 | 23.78 | |
EV/FCF |
73.94 | 46.23 | 61.96 | 61.64 | |
Quick Ratio |
1.88 | 1.98 | 2.21 | 2.23 | |
Current Ratio |
2.38 | 2.46 | 2.82 | 2.80 | |
Net Debt/EBITDA |
13.75 | 13.55 | 17.72 | 13.22 | |
Debt/Assets |
70.22% | 68.48% | 68.96% | 67.47% | |
Debt/Equity |
4.06 | 3.69 | 3.58 | 3.35 | |
Asset Turnover |
0.36 | 0.37 | 0.38 | 0.37 | |
Operating CF/Net income |
1.47 | 2.96 | 1.11 | 1.65 | |
Capex/Depreciation |
(1.22) | (1.49) | (1.43) | (1.33) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
20.33% | 18.95% | 24.36% | 21.21% | |
Intangible Assets out of Total Assets |
0.44 | 0.43 | 0.43 | 0.41 | |
Share Based Compensation of Revenue |
2.55% | 2.49% | 5.14% | 2.25% | |
Graham Net Nets |
(0.46) | (0.41) | (0.50) | (0.39) | |
Graham Number |
2.88 | 3.60 | 4.49 | 5.47 | |
Earnings Yield |
1.21% | 1.53% | 2.86% | 3.21% | |
Free Cash Flow Yield |
1.94% | 2.98% | 2.37% | 2.22% | |
Revenue per Share |
1.10 | 1.07 | 0.98 | 1.12 | |
Operating CF per Share |
0.25 | 0.36 | 0.10 | 0.31 | |
Capex per Share |
(0.13) | (0.18) | (0.16) | (0.16) | |
Free Cash Flow per Share |
0.12 | 0.18 | (0.06) | 0.15 | |
Cash per Share |
1.06 | 1.22 | 1.11 | 1.25 | |
Shareholders Equity per Share |
1.94 | 2.13 | 2.19 | 2.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.94 | 2.13 | 2.19 | 2.33 | |
Free Cash Flow |
34.98 | 52.41 | (16.73) | 42.05 | |
Working Capital |
335.42 | 363.83 | 378.17 | 415.22 | |
Capital Expenditures |
(36.17) | (50.70) | (46.17) | (46.45) | |
Net Current Asset Value |
(2,057.88) | (2,043.74) | (2,027.42) | (1,994.68) | |
EV/EBIT |
18.63 | 19.05 | 15.76 | 17.40 | |
Capex to Sales |
0.12 | 0.17 | 0.16 | 0.14 | |
Net Profit Margin |
15.55% | 11.48% | 9.49% | 16.69% | |
Price to Operating Income |
13.00 | 13.84 | 10.73 | 12.71 | |
| Other line items | |||||
Average Receivables |
149.32 | 147.16 | 138.38 | 153.28 | |
Average Payables |
66.07 | 66.53 | 73.40 | 82.34 | |
Average Inventory |
51.76 | 51.77 | 59.27 | 58.16 | |
Average Assets |
3,167.45 | 3,167.42 | 3,166.71 | 3,261.76 | |
Average Common Equity |
510.32 | 505.47 | 518.30 | 588.47 |
Columns are period end dates